SCHEMBL4996296

SCHEMBL4996296

COC(=O)c1cccn(Cc2cccc(F)c2)c1=O

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.59
POLB P06746 1/20 0.59
PTGER3 P43115 1/20 0.57
ALDH1A1 P00352 5/20 0.55
KDM4E B2RXH2 3/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
SMN1; SMN2 Q16637 3/20 0.54
PDPK1 O15530 1/20 0.54
MEN1 O00255 1/20 0.53
HTT P42858 1/20 0.53
KMT2A Q03164 1/20 0.53
ATM Q13315 1/20 0.52
BRD4 O60885 2/20 0.51
BRD2 P25440 1/20 0.51
BRD3 Q15059 1/20 0.51
BRDT Q58F21 1/20 0.51
TP53 P04637 1/20 0.51
MET P08581 1/20 0.50
AXL P30530 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4817512 0.87 CNR1 (0.59) MAPTPOLBPTGER3ALDH1A1KDM4E
SCHEMBL13306800 0.85 MAPT (0.56) MAPTPOLBALDH1A1KDM4ESMN1; SMN2
SCHEMBL4992274 0.85 MAPT (0.78) MAPTPOLBPTGER3ALDH1A1KDM4E
SCHEMBL4984011 0.85 MAPT (0.59) MAPTPOLBALDH1A1KDM4ESMN1; SMN2
SCHEMBL2621621 0.84 ALDH1A1 (0.59) MAPTPOLBPTGER3ALDH1A1KDM4E
SCHEMBL1137191 0.84 BRD4 (0.70) MAPTPOLBALDH1A1KDM4EL3MBTL1
SCHEMBL4990920 0.84 MAPT (0.61) MAPTPOLBPTGER3ALDH1A1KDM4E
SCHEMBL4997385 0.84 MAPT (0.61) MAPTPOLBPTGER3ALDH1A1KDM4E
SCHEMBL25391826 0.83 L3MBTL1 (0.56) MAPTPTGER3ALDH1A1KDM4EL3MBTL1
SCHEMBL2621676 0.80 MAPT (0.57) MAPTPOLBALDH1A1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 MAPT 4654/4885POLB 4248/4885PTGER3 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.